Drug Target Review: Pinpointing function in cancer T cells could be new immunotherapy
UC research has found that increasing a certain function in cancer T cells could mean a new therapy
A previously unknown T cell mechanism that could explain the reason behind decreased immune function in cancer patients has been discovered. According to University of Cincinnati researchers, their finding may present a new immunotherapeutic target for patients with head and neck cancers.
The study, led by Laura Conforti and Ameet Chimote, in the Division of Nephrology and Hypertension, UC Department of Internal Medicine, revealed that a reduced interaction between a molecule called calmodulin and the ion channel KCa3.1 in the immune cells of cancer patients plays an important role in the limited function of these cells. The team performed experiments on cytotoxic T cells taken from the blood of patients with head and neck cancer.
Featured photo courtesy of Laura Conforti and Ameet Chimote.
Related Stories
Chris Higgins named UC Foundation Vice President for Development, Academic Health Enterprise
January 6, 2026
The University of Cincinnati Foundation is pleased to welcome Chris Higgins as the new Vice President for Development, Academic Health Enterprise.
What's behind the mysterious rise of migraines?
January 5, 2026
Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.
Top six 2025 nephrology drug approvals
January 5, 2026
“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.